SFShawn French

Shawn French

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shawn French has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metals have disparate impacts on lipid mobility in Shewanella putrefaciens CN32

    by Shawn French, Sirine Fakra, Susan Glasauer

    Bacteria are central to soil bioremediation strategies to reduce metal concentrations in soil and water. This requires the cell envelope to maintain structural integrity despite elevated concentrations of cationic. Here we investigate liposomes obtained from extracted S. putrefaciens CN32 phospholipids after culturing CN32 with Mn(II), V(IV) and U(VI), using spectrofluorometric lipid microviscosity assays. Phospholipid diffusion decreased following exposure to 0.01 mM V(IV) and Mn(II); exposure to 0.1 mM concentration decreased phospholipid diffusion for the Mn(II) treatment only. At 1 mM, V(IV) and Mn(II) fluidized the phospholipids. Sub-micron Mn particulates and diffuse Mn were observed using Scanning Transmission X-ray Microscopy (STXM), but vanadium was not detected on the envelopes. In contrast to Mn and V, U impeded diffusion significantly at all concentrations from 0.01 to 1 mM. The mobility of membrane components is critical for bacterial survival and growth. Our results demonstrate that cationic Mn, V and U impose strong abiotic effects on membrane lipid dynamics.

  • Open Access

    Coniontins, lipopetaibiotics active against Candida auris identified from a microbial natural product fractionation library

    by Xuefei Chen, Kalinka Koteva, Sommer Chou, Allison Guitor, Daniel Pallant, Yunjin Lee, David Sychantha, Shawn French, Dirk Hackenberger, Nicole Robbins, et al.

    The rise of drug-resistant fungal pathogens, including Candida auris, highlights the urgent need for innovative antifungal therapies. We have developed a cost-effective platform combining microbial extract prefractionation with rapid mass spectrometry-bioinformatics-based dereplication to efficiently prioritize previously uncharacterized antifungal scaffolds. Screening C. auris and Candida albicans reveals coniotins, lipopeptaibiotics isolated from Coniochaeta hoffmannii, which are undetectable in crude extracts. Coniotins exhibits potent activity against critical priority fungal pathogens listed by the World Health Organization, including C. albicans, Cryptococcus neoformans, multidrug-resistant Candida auris, and Aspergillus fumigatus, with high selectivity and low resistance potential. Coniotin A targets beta-glucan, compromising fungal cell wall integrity, remodelling, and sensitizing C. auris to caspofungin. Identification of its hybrid polyketide synthase-nonribosomal peptide synthetase biosynthetic gene cluster facilitates discovering structurally diverse lipopeptaibiotics. Here, we show that natural product prefractionation enables the discovery of previously hidden bioactive scaffolds and introduces coniotins as candidates for combating multidrug-resistant fungal pathogens.


  • Open Access

    A microbial natural product fractionation library screen with HRMS/MS dereplication identifies new lipopeptaibiotics against Candida auris

    by Gerard Wright, Xuefei Chen, Kalinka Koteva, Sommer Chou, Allison Guitor, Daniel Pallant, Yunjin Lee, David Sychantha, Shawn French, Dirk Hackenberger, et al.

    The rise of drug-resistant fungal pathogens, including Candida auris, highlights the urgent need for novel antifungal therapies. We developed a cost-effective platform combining microbial extract prefractionation with rapid MS/MS-bioinformatics-based dereplication to efficiently prioritize new antifungal scaffolds. Screening C. auris and C. albicans revealed novel lipopeptaibiotics, coniotins, from Coniochaeta hoffmannii WAC11161, which were undetectable in crude extracts. Coniotins exhibited potent activity against critical fungal pathogens on the WHO Fungal Priority Pathogens List, including C. albicans, C. neoformans, multidrug-resistant C. auris, and Aspergillus fumigatus, with high selectivity and low resistance potential. Coniotin A targets β-glucan, compromising fungal cell wall integrity, remodelling, and sensitizing C. auris to caspofungin. Identification of a PKS-NRPS biosynthetic gene cluster further enables the discovery of related clusters encoding potential novel lipopeptaibiotics. This study demonstrates the power of natural product prefractionation in uncovering bioactive scaffolds and introduces coniotins as promising candidates for combating multidrug-resistant fungal pathogens.

  • Exploiting the fitness cost of metallo-β-lactamase expression can overcome antibiotic resistance in bacterial pathogens

    by Megan M. Tu, Lindsey A. Carfrae, Kenneth Rachwalski, Shawn French, Denise Catacutan, Rodion Gordzevich, Craig R. MacNair, Melissa E. Speagle, Firas Werah, Jonathan M. Stokes, et al.

    Carbapenems are last-resort antibiotics for treating bacterial infections. The widespread acquisition of metallo-β-lactamases, such as VIM-2, contributes to the emergence of carbapenem-resistant pathogens, and currently, no metallo-β-lactamase inhibitors are available in the clinic. Here we show that bacteria expressing VIM-2 have impaired growth in zinc-deprived environments, including human serum and murine infection models. Using transcriptomic, genomic and chemical probes, we identified molecular pathways critical for VIM-2 expression under zinc limitation. In particular, disruption of envelope stress response pathways reduced the growth of VIM-2-expressing bacteria in vitro and in vivo. Furthermore, we showed that VIM-2 expression disrupts the integrity of the outer membrane, rendering VIM-2-expressing bacteria more susceptible to azithromycin. Using a systemic murine infection model, we showed azithromycin’s therapeutic potential against VIM-2-expressing pathogens. In all, our findings provide a framework to exploit the fitness trade-offs of resistance, potentially accelerating the discovery of additional treatments for infections caused by multidrug-resistant bacteria.


  • Open Access

    A platform for predicting mechanism of action based on bacterial transcriptional responses identifies an unusual DNA gyrase inhibitor

    by Shawn French, Amelia Bing Ya Guo, Michael J. Ellis, Julia P. Deisinger, Jarrod W. Johnson, Kenneth Rachwalski, Zoë A. Piquette, Telmah Lluka, Miranda Zary, Sineli Gamage, et al.


  • Open Access

    The fitness cost of metallo-β-lactamase expression is a potential target for new therapeutic approaches to carbapenem resistance

    by Megan Tu, Lindsey Carfrae, Kenneth Rachwalski, Shawn French, Denise Catacutan, Rodion Gordzevich, Craig MacNair, Melissa Speagle, Firas Werah, Jonathan Stokes, et al.

    Carbapenem antibiotics represent the most reliable last-resort treatment for bacterial infections. The widespread acquisition of metallo-β-lactamases (MBLs), such as VIM-2, is a significant contributor to the emergence of carbapenem-resistant pathogens. The absence of clinically available MBL inhibitors necessitates the development of new approaches to treat carbapenem-resistant infections. Herein, we demonstrate that Enterobacteriaceae and Pseudomonas aeruginosa expressing VIM-2 have impaired growth in clinically relevant zinc-deprived environments, including human serum and murine infection models. Using transcriptomic, genomic, and chemical probes, we identified molecular pathways critical for VIM-2 expression in Escherichia coli under zinc limitation. Of particular note were envelope stress response pathways. Disruption of envelope stress response pathways significantly reduced the growth of VIM-2-expressing bacteria in vitro and in vivo. Furthermore, we demonstrated that VIM-2 expression disrupts the integrity of the outer membrane, rendering VIM-2-expressing bacteria more susceptible to antibiotics that are typically ineffective against Gram-negative bacteria, such as azithromycin. Accordingly, using a systemic murine infection model, we revealed that azithromycin has therapeutic potential in treating VIM-2-expressing Klebsiella pneumoniae. In all, our findings provide a framework to uncover and exploit the fitness trade-offs of resistance, potentially accelerating the discovery of novel treatments for multi-drug resistant bacteria.


  • Inhibiting fatty acid synthesis overcomes colistin resistance

    by Lindsey A. Carfrae, Kenneth Rachwalski, Shawn French, Rodion Gordzevich, Laura Seidel, Caressa N. Tsai, Megan M. Tu, Craig R. MacNair, Olga G. Ovchinnikova, Bradley R. Clarke, et al.

    Treating multidrug-resistant infections has increasingly relied on last-resort antibiotics, including polymyxins, for example colistin. As polymyxins are given routinely, the prevalence of their resistance is on the rise and increases mortality rates of sepsis patients. The global dissemination of plasmid-borne colistin resistance, driven by the emergence of mcr-1, threatens to diminish the therapeutic utility of polymyxins from an already shrinking antibiotic arsenal. Restoring sensitivity to polymyxins using combination therapy with sensitizing drugs is a promising approach to reviving its clinical utility. Here we describe the ability of the biotin biosynthesis inhibitor, MAC13772, to synergize with colistin exclusively against colistin-resistant bacteria. MAC13772 indirectly disrupts fatty acid synthesis (FAS) and restores sensitivity to the last-resort antibiotic, colistin. Accordingly, we found that combinations of colistin and other FAS inhibitors, cerulenin, triclosan and Debio1452-NH3, had broad potential against both chromosomal and plasmid-mediated colistin resistance in chequerboard and lysis assays. Furthermore, combination therapy with colistin and the clinically relevant FabI inhibitor, Debio1452-NH3, showed efficacy against mcr-1 positive Klebsiella pneumoniae and colistin-resistant Escherichia coli systemic infections in mice. Using chemical genomics, lipidomics and transcriptomics, we explored the mechanism of the interaction. We propose that inhibiting FAS restores colistin sensitivity by depleting lipid synthesis, leading to changes in phospholipid composition. In all, this work reveals a surprising link between FAS and colistin resistance.


  • Open Access

    Central metabolism is a key player in E. coli biofilm stimulation by sub-MIC antibiotics

    by Luke N. Yaeger, Shawn French, Eric D. Brown, Jean Philippe Côté, Lori L. Burrows

    Exposure of Escherichia coli to sub-inhibitory antibiotics stimulates biofilm formation through poorly characterized mechanisms. Using a high-throughput Congo Red binding assay to report on biofilm matrix production, we screened ∼4000 E. coli K12 deletion mutants for deficiencies in this biofilm stimulation response. Mutants lacking acnA, nuoE , or lpdA failed to respond to sub-MIC novobiocin, implicating central metabolism and aerobic respiration in biofilm stimulation. These genes are members of the ArcA/B regulon – controlled by a respiration-sensitive two-component system. Mutants of arcA and arcB had a ‘pre-activated’ phenotype, where biofilm formation was already high relative to wild type in vehicle control conditions and failed to increase further with the addition of sub-MIC antibiotics. Supporting a role for respiratory stress, the biofilm stimulation response was inhibited when nitrate was provided as an alternative electron acceptor. Deletion of genes encoding the nitrate respiratory machinery abolished its effects, and nitrate respiration increased during growth with sub-MIC antibiotics. In probing the generalizability of biofilm stimulation, we found that the stimulation response to translation inhibitors was minimally affected by nitrate supplementation. Finally, using a metabolism-sensitive dye, we showed spatial co-localization of increased respiration with sub-MIC bactericidal antibiotics. By characterizing the biofilm stimulation response to sub-MIC antibiotics at a systems level, we identified multiple avenues for design of therapeutics that impair bacterial stress management.


  • Chemical Screen for Vancomycin Antagonism Uncovers Probes of the Gram-Negative Outer Membrane

    by Kristina Klobucar, Jean-Philippe Côté, Shawn French, Louis Borrillo, Amelia Bing Ya Guo, Michael H. Serrano-Wu, Katie K. Lee, Brian Hubbard, Jarrod W. Johnson, Jeffrey L. Gaulin, et al.

    The outer membrane of Gram-negative bacteria is a formidable permeability barrier which allows only a small subset of chemical matter to penetrate. This outer membrane barrier can hinder the study of cellular processes and compound mechanism of action, as many compounds including antibiotics are precluded from entry despite having intracellular targets. Consequently, outer membrane permeabilizing compounds are invaluable tools in such studies. Many existing compounds known to perturb the outer membrane also impact inner membrane integrity, such as polymyxins and their derivatives, making these probes nonspecific. We performed a screen of ∼140 000 diverse synthetic compounds, for those that antagonized the growth inhibitory activity of vancomycin at 15 °C in Escherichia coli, to enrich for chemicals capable of perturbing the outer membrane. This led to the discovery that liproxstatin-1, an inhibitor of ferroptosis in human cells, and MAC-0568743, a novel cationic amphiphile, could potentiate the activity of large-scaffold antibiotics with low permeation into Gram-negative bacteria at 37 °C. Liproxstatin-1 and MAC-0568743 were found to physically disrupt the integrity of the outer membrane through interactions with lipopolysaccharide in the outer leaflet of the outer membrane. We showed that these compounds selectively disrupt the outer membrane while minimally impacting inner membrane integrity, particularly at the concentrations needed to potentiate Gram-positive-targeting antibiotics. Further exploration of these molecules and their structural analogues is a promising avenue for the development of outer membrane specific probes.


  • Systems-Level Chemical Biology to Accelerate Antibiotic Drug Discovery

    by Maya A. Farha, Shawn French, Eric D. Brown

    Drug-resistant bacterial infections pose an imminent and growing threat to public health. The discovery and development of new antibiotics of novel chemical class and mode of action that are unsusceptible to existing resistance mechanisms is imperative for tackling this threat. Modern industrial drug discovery, however, has failed to provide new drugs of this description, as it is dependent largely on a reductionist genes-to-drugs research paradigm. We posit that the lack of success in new antibiotic drug discovery is due in part to a lack of understanding of the bacterial cell system as whole. A fundamental understanding of the architecture and function of bacterial systems has been elusive but is of critical importance to design strategies to tackle drug-resistant bacterial pathogens. Increasingly, systems-level approaches are rewriting our understanding of the cell, defining a dense network of redundant and interacting components that resist perturbations of all kinds, including by antibiotics. Understanding the network properties of bacterial cells requires integrative, systematic, and genome-scale approaches. These methods strive to understand how the phenotypic behavior of bacteria emerges from the many interactions of individual molecular components that constitute the system. With the ability to examine genomic, transcriptomic, proteomic, and metabolomic consequences of, for example, genetic or chemical perturbations, researchers are increasingly moving away from one-gene-at-a-time studies to consider the system-wide response of the cell. Such measurements are demonstrating promise as quantitative tools, powerful discovery engines, and robust hypothesis generators with great value to antibiotic drug discovery. In this Account, we describe our thinking and findings using systems-level studies aimed at understanding bacterial physiology broadly and in uncovering new antibacterial chemical matter of novel mechanism. We share our systems-level toolkit and detail recent technological developments that have enabled unprecedented acquisition of genome-wide interaction data. We focus on three types of interactions: gene–gene, chemical–gene, and chemical–chemical. We provide examples of their use in understanding cell networks and how these insights might be harnessed for new antibiotic discovery. By example, we show the application of these principles in mapping genetic networks that underpin phenotypes of interest, characterizing genes of unknown function, validating small-molecule screening platforms, uncovering novel chemical probes and antibacterial leads, and delineating the mode of action of antibacterial chemicals. We also discuss the importance of computation to these approaches and its probable dominance as a tool for systems approaches in the future. In all, we advocate for the use of systems-based approaches as discovery engines in antibacterial research, both as powerful tools and to stimulate innovation.